首页> 外文OA文献 >Clinical Significance of Serum IL-12 Level in Patients with Early Breast Carcinoma and Its Correlation with Other Tumor Markers
【2h】

Clinical Significance of Serum IL-12 Level in Patients with Early Breast Carcinoma and Its Correlation with Other Tumor Markers

机译:早期乳腺癌患者血清IL-12水平的临床意义及其与其他肿瘤标志物的相关性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

AIM: To investigate the diagnostic significance of Interleukin 12 (IL-12) in breast cancer (BC) and its correlation with other tumor markers including cancer antigen 15-3 (CA 15-3), carcinoembryonic antigen (CEA), matrix metalloproteinase-9 (MMP-9), tissue inhibitor of metalloproteinases-1 (TIMP-1), and MMP9/TIMP1 ratio.METHODS: Serum levels of IL-12, tumor markers, and hormone receptors were measured in 92 BC and 56 benign lesion patients versus 40 healthy subjects. Clinical stage, tumor size, lymph node metastasis, grade, and histological type were recorded.RESULTS: BC patients have lower IL-12, but higher CA 15.3 and CEA than control group. High levels of serum IL-12 were associated with lymph node positivity and progesterone receptor negativity. IL-12 was significant lower in invasive ductal carcinoma (IDC) compared to non IDC histological type. IL-12 was higher in patients with higher stage and grade but the difference was not statistically significant.IL-12 correlates negatively with MMP9/TIMP1 ratio.CONCLUSION: IL-12 is less specific than CEA for screening early BC, but its correlation with tumor aggressiveness and progression markers may have a prognostic value.
机译:目的:研究白介素12(IL-12)在乳腺癌(BC)中的诊断意义及其与其他肿瘤标志物的相关性,包括癌症抗原15-3(CA 15-3),癌胚抗原(CEA),基质金属蛋白酶- 9(MMP-9),金属蛋白酶-1(TIMP-1)的组织抑制剂和MMP9 / TIMP1比值方法:在92 BC和56例良性病变患者中测量了血清IL-12,肿瘤标志物和激素受体的水平对比40名健康受试者。记录临床分期,肿瘤大小,淋巴结转移,分级和组织学类型。结果:BC组患者IL-12水平较低,但CA 15.3和CEA水平高于对照组。血清IL-12水平高与淋巴结阳性和孕激素受体阴性有关。与非IDC组织学类型相比,浸润性导管癌(IDC)中的IL-12显着降低。 IL-12在较高分期和分级的患者中较高,但差异无统计学意义。IL-12与MMP9 / TIMP1比值呈负相关。结论:IL-12在筛查早期BC时不如CEA特异,但与CEA的筛查有关肿瘤侵袭性和进展标志物可能具有预后价值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号